Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice

Speaker: Yi (Benny) Yang, Ph.D.  Chief Scientific Officer, Biocytogen Beijing

• Introduced Biocytogen’s next-generation fully human bispecific antibody development platform, which has facilitated drug discovery for more than two hundred TAA (tumor associated antigen) targets
• Analyzed the design, screening and drug discovery of bispecific antibodies and bispecific-ADC drugs in two case studies